Navigation Links
Connection discovered between the nervous system and the vascular system
Date:6/8/2011

Montral, June 8, 2011 Dr. Frdric Charron, researcher at the Institut de recherches cliniques de Montral (IRCM), and his team have shown for the first time that a key molecule of the vascular system directs axons during the formation of neural circuits. This connection between the nervous system and the vascular system could be a good starting point for the development of therapies for neurodegenerative diseases. The discovery will be published tomorrow by Neuron, a scientific journal of the Cell Press group.

"To properly form neural circuits, developing axons (long extensions of neurons that make the nerves) need molecules to guide them towards their target, in the same way that road signs guide us when we drive," explains Pierre Fabre, doctoral student in Dr. Charron's team and first co-author of the article.

The nervous system is not the only system formed during human embryo development. Blood vessels are also organized into a very complex network, which led to the idea that certain molecules could be reused by both the nervous system and the vascular system. In fact, recent studies revealed that the reference points used to guide axons also help blood vessels reach their targets.

"One of the key molecules of the vascular system is the vascular endothelial growth factor, better known as VEGF," adds Mr. Fabre. "We discovered that VEGF is able to attract nervous system axons. More specifically, we identified Flk-1 as the receptor responsible for this effect, making it a prime target for the development of therapies to re-grow axons after lesions of the central nervous system or neurodegenerative diseases."

This scientific breakthrough was possible due to an innovative technique developed by Dr. Charron's laboratory a few years ago. The system uses a microscopic device to control and observe, in real time, the axon's behaviour in response to guidance molecules. This technique allowed the researchers to follow the axon's trajectory and revealed VEGF's role in directing axons.

"This research could have an important long-term impact in the field of spinal cord repair, as the results will help us better understand the development of the spinal cord," says Dr. Charron, Director of the IRCM's Molecular Biology of Neural Development research unit. "The more we learn about the molecules needed to appropriately guide axons, the more it will become possible to develop a therapy to treat spinal cord injuries."

"These new findings are of great interest to the research community as they offer new hope for the treatment of neurodegenerative diseases," says Dr. Anthony Phillips, CIHR's Scientific Director of the Institute of Neurosciences, Mental Health and Addiction. "CIHR recognizes the important work of Dr. Charron's team and this novel discovery linking blood vessels and neurons to neural circuit formation."


'/>"/>

Contact: Julie Langelier
julie.langelier@ircm.qc.ca
514-987-5555
Institut de recherches cliniques de Montreal
Source:Eurekalert

Related medicine news :

1. Home Health Agency Owner Pleads Guilty in Connection with Detroit Fraud Scheme
2. New tool illuminates connections between stem cells and cancer
3. Three Houston Defendants Plead Guilty in Connection with "Arthritis Kit" Fraud Scheme
4. Strategic Connections Inc. (SCI) Announces Market Expansion and New Brand
5. Announcing the Evolution of Provider Placement Methodology – EPIC Connections
6. The creative engagement and cardiac health connection disclosed
7. Strategic Connections Ranks 90th Fastest-Growing Technology Company in North America and 14th in Canada
8. Khanna Institute of Vision and Your Health Connection Spring Expo
9. New NACDS Chairman Larry Merlo Emphasizes Personal Commitment, Connection to Pharmacy
10. Harmony Information Systems Selected to Present at Exclusive MAVA Capital Connection 2010 Event
11. World-Renowned Spiritual Master Panache Desai Brings The Power of Connection™ to More than 20 States Throughout the Remainder of 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: